LAVAL, QC, July 14 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS) today announced that it will host a conference call on Wednesday, July 28, 2004 at 8:30 a.m. (ET) to discuss its second quarter fiscal 2004 results. Labopharm will report its second quarter fiscal 2004 results via news release at approximately 7:00 a.m. the same day. To access the conference call by telephone, dial 416-405-9328 or 1-800-387-6216. Please connect approximately fifteen minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Wednesday, August 4, 2004 at midnight. To access the archived conference call, dial 416-695-5800 or 1-800-408-3053 and enter the reservation number 3080881 followed by the number sign. A live audio webcast of the conference call will be available at www.labopharm.com and www.financialdisclosure.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web sites for 90 days. About Labopharm Inc. Labopharm Inc. (TSX:DDS) is an international specialty pharmaceutical company focused on the development of drugs incorporating the Company's proprietary advanced controlled-release technology, Contramid(R). Contramid(R) can be applied to a wide variety of drugs in solid oral dosage form, improving their oral administration and performance and is used to develop products that are either bio-equivalent to existing, branded products, or are new branded products. The Company's pipeline includes a combination of both in-house and partnered programs with products both in clinical trials and in preclinical development. Labopharm is also developing implantable mini-tablets based on Contramid(R) for local administration of drugs and novel polymeric nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs. For more information, please visit www.labopharm.com. This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of clinical studies, the uncertainties related to the regulatory process and the commercialization of the drug thereafter. Investors should consult the Corporation's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
SOURCE Labopharm Inc.